Patents by Inventor Wolfgang Fraunhofer

Wolfgang Fraunhofer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190231978
    Abstract: A wearable automatic injection device is provided for administering a final medicament to a patient. The wearable automatic injection device comprises a housing, an injection assembly for injecting the patient with the final medicament, a container holding a bulk intermediate medicament and a diluent to be mixed to form the medicament, and a mixing mechanism for mixing the bulk intermediate medicament and the diluent in the container to form the final medicament prior. A system for administering a final medicament to a patient is also provided. The system comprises a container, a mixing mechanism for mixing a bulk intermediate medicament and a diluent in the container to form the final medicament, and a wearable automatic injection device configured to receive the container.
    Type: Application
    Filed: January 18, 2019
    Publication date: August 1, 2019
    Inventors: Wolfgang Fraunhofer, James Cameron, Linas P. Laurusonis
  • Publication number: 20190211093
    Abstract: The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.
    Type: Application
    Filed: August 10, 2018
    Publication date: July 11, 2019
    Inventors: Michael Neu, Markus Tschoepe, Carsten Weber, Wolfgang Fraunhofer, Laura Redden, Martin Gastens, Alexander Feick, Susan K. Paulson, Tong Zhu
  • Patent number: 10183117
    Abstract: A wearable automatic injection device is provided for administering a final medicament to a patient. The wearable automatic injection device comprises a housing, an injection assembly for injecting the patient with the final medicament, a container holding a bulk intermediate medicament and a diluent to be mixed to form the medicament, and a mixing mechanism for mixing the bulk intermediate medicament and the diluent in the container to form the final medicament prior. A system for administering a final medicament to a patient is also provided. The system comprises a container, a mixing mechanism for mixing a bulk intermediate medicament and a diluent in the container to form the final medicament, and a wearable automatic injection device configured to receive the container.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: January 22, 2019
    Assignee: AbbVie Inc.
    Inventors: Wolfgang Fraunhofer, James Cameron, Linas P. Laurusonis
  • Publication number: 20170143828
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductivity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Application
    Filed: February 2, 2017
    Publication date: May 25, 2017
    Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
  • Publication number: 20160222101
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductivity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Application
    Filed: April 11, 2016
    Publication date: August 4, 2016
    Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
  • Publication number: 20160106921
    Abstract: A wearable automatic injection device is provided for administering a final medicament to a patient. The wearable automatic injection device comprises a housing, an injection assembly for injecting the patient with the final medicament, a container holding a bulk intermediate medicament and a diluent to be mixed to form the medicament, and a mixing mechanism for mixing the bulk intermediate medicament and the diluent in the container to form the final medicament prior. A system for administering a final medicament to a patient is also provided. The system comprises a container, a mixing mechanism for mixing a bulk intermediate medicament and a diluent in the container to form the final medicament, and a wearable automatic injection device configured to receive the container.
    Type: Application
    Filed: October 16, 2015
    Publication date: April 21, 2016
    Inventors: Wolfgang Fraunhofer, James Cameron, Linas P. Laurusonis
  • Publication number: 20160017030
    Abstract: The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.
    Type: Application
    Filed: July 30, 2015
    Publication date: January 21, 2016
    Inventors: Michael Neu, Markus Tschoepe, Carsten Weber, Wolfgang Fraunhofer, Laura Redden, Martin Gastens, Alexander Feick, Susan K. Paulson, Tong Zhu
  • Publication number: 20150361170
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Application
    Filed: July 10, 2015
    Publication date: December 17, 2015
    Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
  • Patent number: 9085619
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: July 21, 2015
    Assignee: AbbVie Biotechnology LTD.
    Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe
  • Publication number: 20150183863
    Abstract: The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said crystals as well as methods of use of said crystals and compositions.
    Type: Application
    Filed: June 19, 2014
    Publication date: July 2, 2015
    Inventors: David W. Borhani, Wolfgang Fraunhofer, Hans-Juergen Krause, Anette Koenigsdorfer, Gerhard Winter, Stefan Gottschalk
  • Publication number: 20150166648
    Abstract: The present invention relates to a batch crystallization method for crystallizing anti-human TNFalpha (hTNFalpha) antibody and antibody fragments which allows the production of said antibody on an industrial scale; a method of controlling the size of antibody crystals, for example, crystals of anti-hTNFalpha antibody fragments, compositions containing said crystals as well as methods of use of said crystals and compositions.
    Type: Application
    Filed: June 5, 2014
    Publication date: June 18, 2015
    Inventors: Wolfgang Fraunhofer, David W. Borhani, Gerhard Winter, Stefan Gottschalk
  • Publication number: 20150071944
    Abstract: The invention provides compositions and methods for inhibiting fractionation of immunoglobulins comprising a lambda light chain based on the observation that iron, in the presence of histidine, results in increased fragmentation of a recombinant fully human IgG molecule containing a lambda light chain due to cleavage in the hinge region. The invention further provides an aqueous pharmaceutical formulation comprising an antibody, or antigen-binding portion thereof, that binds the p40 subunit of IL-12/IL-23 and a buffer system comprising histidine, wherein the formulation has enhanced stability, including enhanced resistance to fragmentation.
    Type: Application
    Filed: November 6, 2014
    Publication date: March 12, 2015
    Inventors: Ivan R.S. Correia, Czeslaw H. Radziejewski, Wolfgang Fraunhofer, Nicholas William Warne, Angela Kantor
  • Patent number: 8940873
    Abstract: The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: January 27, 2015
    Assignee: AbbVie Inc.
    Inventors: David W. Borhani, Wolfgang Fraunhofer, Hans-Juergen Krause, Anette Koenigsdorfer, Gerhard Winter, Stefan Gottschalk
  • Publication number: 20150023977
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Application
    Filed: October 3, 2014
    Publication date: January 22, 2015
    Applicant: ABBVIE INC.
    Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
  • Publication number: 20140377275
    Abstract: The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.
    Type: Application
    Filed: August 29, 2014
    Publication date: December 25, 2014
    Inventors: Michael Neu, Markus Tschoepe, Carsten Weber, Wolfgang Fraunhofer, Laura Redden, Martin Gastens, Alexander Feick, Susan K. Paulson, Tong Zhu
  • Patent number: 8883146
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: November 11, 2014
    Assignee: AbbVie Inc.
    Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
  • Patent number: 8821865
    Abstract: The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: September 2, 2014
    Assignee: Abbvie Biotechnology Ltd.
    Inventors: Michael Neu, Markus Tschoepe, Carsten Weber, Wolfgang Fraunhofer, Laura Redden, Martin Gastens, Alexander Feick
  • Patent number: 8772458
    Abstract: The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said crystals as well as methods of use of said crystals and compositions.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: July 8, 2014
    Assignee: AbbVie Biotechnology Ltd
    Inventors: Anette Koenigsdorfer, Stefan Gottschalk, Hans-Juergen Krause, Gerhard Winter, David W. Borhani, Wolfgang Fraunhofer
  • Patent number: 8753839
    Abstract: The present invention relates to a batch crystallization method for crystallizing anti-human TNFalpha (hTNFalpha) antibody and antibody fragments which allows the production of said antibody on an industrial scale; a method of controlling the size of antibody crystals, for example, crystals of anti-hTNFalpha antibody fragments, compositions containing said crystals as well as methods of use of said crystals and compositions.
    Type: Grant
    Filed: August 8, 2008
    Date of Patent: June 17, 2014
    Assignee: Abbvie Inc.
    Inventors: Wolfgang Fraunhofer, David W. Borhani, Gerhard Winter, Stefan Gottschalk
  • Publication number: 20140141007
    Abstract: The invention provides a liquid pharmaceutical formulation which does not include NaCl and comprises more than 20 mg of a polyol and at least about 100 mg/mL of a human anti-TNF-alpha antibody, or antigen-binding portion thereof. The invention provides a high concentration antibody formulation having long-term stability and advantageous characteristics for subcutaneous administration.
    Type: Application
    Filed: January 31, 2014
    Publication date: May 22, 2014
    Inventors: Wolfgang Fraunhofer, Hans-Juergen Krause, Michael Neu